The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis

Rosanel Amaro, Meropi Panagiotaraka, Victoria Alcaraz, Antoni Torres

Producció científica: Article en revista indexadaArticle de revisió (sistemàtica)Avaluat per experts

7 Cites (Scopus)


Introduction: Non-cystic fibrosis bronchiectasis (NCFB) is considered a chronic heterogenic pulmonary disease, characterized by the permanent and abnormal enlargement and thickening of bronchial walls, impaired mucociliary clearance, and suppuration. Inhaled antibiotics have been used for a long time in patients with cystic fibrosis but are seldom used in those with NCFB and few randomized clinical trials are available in this population. Areas covered: This review summarizes current clinical evidence of efficacy, adverse events, and future directions of inhaled antibiotics in NCFB. Expert commentary: Inhaled antibiotics are theoretically a promising therapeutic option for patients with NCFB, owing to the achieved high pulmonary concentrations and the irrelevant systemic adverse effects. In the era of multidrug resistance, we call for comprehensive clinical trials in this field to corroborate the merits of inhaled antibiotics in NCFB patients.

Idioma originalAnglès
Pàgines (de-a)683-691
Nombre de pàgines9
RevistaExpert Review of Respiratory Medicine
Estat de la publicacióPublicada - 3 d’ag. 2018
Publicat externament


Navegar pels temes de recerca de 'The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis'. Junts formen un fingerprint únic.

Com citar-ho